IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

MLA

Dubbink HJ, et al. “IDH1 Mutations in Low-Grade Astrocytomas Predict Survival but Not Response to Temozolomide.” Neurology, vol. 73, no. 21, Nov. 2009, pp. 1792–95. EBSCOhost, https://doi.org/10.1212/WNL.0b013e3181c34ace.

APA

Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ, Dubbink, H. J., Taal, W., van Marion, R., Kros, J. M., & van Heuvel, I. (2009). IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology, 73(21), 1792–1795. https://doi.org/10.1212/WNL.0b013e3181c34ace

Chicago

Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, et al. 2009. “IDH1 Mutations in Low-Grade Astrocytomas Predict Survival but Not Response to Temozolomide.” Neurology 73 (21): 1792–95. doi:10.1212/WNL.0b013e3181c34ace.